![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Departments of Neurology and Applied Physiology, University of Ulm, Ulm, Germany (T.V.W., S.B., S.M., H.L.); and Department of Physiology, University of Tübingen, Tübingen, Germany (G.S.)
Received December 22, 2004; accepted January 19, 2005
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). Although 60 to 80% of patients with epilepsy respond well to treatment with available anticonvulsant drugs, approximately 30% are pharmacoresistent (Löscher, 1998). Therefore, there is a need to develop new anticonvulsants, which best should have mechanisms of action different from those currently in use, to enlarge the possibilities of differential treatment in mono- and polytherapy. Retigabine (RTG), a novel anticonvulsant, perfectly fulfills these criteria. Its main molecular mechanism of action is activation of the M current (Main et al., 2000; Rundfeldt and Netzer, 2000; Wickenden et al., 2000; Tatulian et al., 2001), a potassium conductance regulating the excitability in a wide variety of neuronal cells (Brown and Adams, 1980). None of the anticonvulsants that are in clinical use today has a comparable mechanism of action. RTG is effective in a broad range of epilepsy and seizure models (Rostock et al., 1996; Tober et al., 1996; Armand et al., 1999, 2000; Dost and Rundfeldt, 2000). In two models of drug-resistant epilepsy, it was the only compound able to antagonize hyperexcitability in a concentration-dependent manner (Armand et al., 1999, 2000) and was also effective in human brain slices derived from patients with pharmacoresistent epilepsy who underwent epilepsy surgery (Straub et al., 2001).
The M current is a slowly activating and noninactivating neuronal potassium conductance blocked via the activation of muscarinergic acetylcholine receptors (Brown and Adams, 1980). Its main molecular correlates are potassium channels of the KCNQ family (Wang et al., 1998). Five members have been cloned to date (genes: KCNQ1-5; proteins: Kv7.1-5) (Gutman et al., 2003), four of which (KCNQ1-4) are involved in hereditary diseases. These include a rare dominant form of epilepsy, benign familial neonatal convulsions, caused by mutations in KCNQ2 and KCNQ3 (Jentsch, 2000; Lerche et al., 2005). RTG activates the neuronal channels Kv7.2 to -5 but not the cardiac Kv7.1 (Tatulian et al., 2001; Dupuis et al., 2002), which is an important prerequisite for the drug to avoid cardiac side effects. The main molecular mechanism of action is a large hyperpolarizing shift in the voltage-dependence of channel activation found for Kv7.2, Kv7.3, and Kv7.5. Therefore, RTG induces an opening of KCNQ channels at the resting membrane potential, shifting it toward the potassium equilibrium potential (EK), a very powerful anticonvulsant mechanism.
The aim of our study was to identify the binding site of RTG in Kv7.2 channels and to reveal the molecular mechanism of channel activation. Chimeras systematically introducing different parts of Kv7.1 into Kv7.2 revealed that RTG binds within the pore region. More detailed experiments, using point mutations in both channels and certain chimeras, indicated that RTG stabilizes the open-pore conformation by binding to the channel's activation gate between the cytoplasmic parts of the S5 and S6 segments. The structure of bacterial potassium channels (Doyle et al., 1998; Jiang et al., 2002) was then used to develop a model for the potential binding site, suggesting a binding pocket formed by the open channel's S5 and S6 segments.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Oocyte Preparation and Injection. All procedures met the National Institute of Health guidelines for the care and use of laboratory animals and were approved by the Regierungspraesidium Tuebingen, Germany. Tricaine (0.1%; Sigma Chemie, Deisenhofen, Germany) was used to anesthetize female Xenopus laevis frogs. Oocytes were obtained surgically and immediately treated for 2 h by collagenase (2 mg/ml type CLS III collagenase; Biochrom, Berlin, German) in OR2 solution (82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2 and 5 mM HEPES, pH 7.6) to remove follicular structures. Defolliculated oocytes were stored at 18°C in frog Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES, pH 7.4) supplemented with 1% fetal calf serum and 50 µg/ml gentamicin (Biochrom). Diluted cRNA (10-20 ng) was injected into each oocyte within 24 h after preparation. Electrophysiological measurements were performed 2 to 5 days after injection.
Electrophysiology. Potassium currents were recorded using standard two-microelectrode voltage clamp, a Turbo TEC01C amplifier (NPI Electronic GmbH, Tamm, Germany) and pClamp data acquisition (Axon Instruments Inc., Union City, CA), as described previously (Lerche et al., 1999). Frog Ringer's solution (see above) was used as the bathing solution for all recordings. RTG was dissolved in dimethyl sulfoxide to obtain 1000-fold concentrated stock solutions for final concentrations of 0.1, 1, 10, and 100 µM. Aliquots of each concentration were stored at -20°C, unfrozen, and directly diluted in frog Ringer's solution on the day electrophysiological experiments were performed. The maximal concentration of dimethyl sulfoxide did not exceed 1 ml per 100 liters.
Recording electrodes were filled with 3 M KCl and had a resistance of 0.3 to 1 M
. Oocytes had resting membrane potentials between -30 and -75 mV. Currents were low-pass-filtered at 0.3 kHz and sampled at 1 kHz. Oocytes were clamped to a membrane potential of -100 mV followed by depolarizing 20-mV steps up to +20 mV. Tail currents were measured at -30 mV, and their amplitudes were analyzed to obtain conductance-voltage plots. To obtain dose-response curves for RTG, oocytes were superfused with increasing concentrations of RTG (0.1, 1, 10, and 100 µM) using a home-made multibarrel application system.
Data were analyzed using pClamp, Microsoft Excel (Microsoft, Redmond, WA), and Origin (OriginLab Corp., Northampton, MA) software. For statistical evaluation, Student's t test was applied. All data are shown as means ± S.E.M. Conductance-voltage curves are fit to the Boltzmann equation I/Imax (V) = 1/(1 + exp[(V - V0.5)/k]), where I/Imax is the normalized tail current amplitude, V0.5 is the voltage of half-maximal activation, and k is a slope factor. All semi-logarithmic plots of RTG response against RTG concentration represent fits to a logistic (or Hill) function according to the following equation: Response = A2 + [(A1 - A2)/(1 + (x/x0)nH)], where A1 is the initial response, A2 the final response, x is the drug concentration, x0 is the EC50, and nH is the slope (Hill coefficient) of the curve.
Modeling. The MthK channel structure (1LNQ) and the KcsA channel structure (1BL8) were retrieved from the Protein Data Bank. A three-dimensional structural model of the S5 to S6 domains of Kv7.2 were constructed on the basis of homology to MthK/KscA using the solved crystal structures of the corresponding domains. The Kv7.2 models were generated using SWISS-MODEL (http://www.expasy.org/swissmod/SWISS-MODEL.html) and were energy-optimized using Gromos96 in default settings within the Swiss-PdbViewer (Guex and Peitsch, 1997). Manual docking of eight energy-optimized RTG conformers (ACD/Chemsketch; Advanced Chemistry Development, Inc., Toronto, ON, Canada) in the Kv7.2 homology models were performed. The resulting model was subsequently energy-optimized using Gromos96. The model with the most likely binding conformation is represented here.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Effects of RTG on Kv7.1 and Kv7.2 WT Channels. Effects of RTG on currents conducted by Kv7.1 and Kv7.2 channels are shown in Fig. 2. The drug had no significant effect on the voltage dependence of activation of WT Kv7.1 channels (Fig. 2C), but in a concentration of 100 µM, it slightly reduced current amplitudes (Fig. 2A) (Tatulian et al., 2001). In contrast, the voltage dependence of steady-state activation of WT Kv7.2 channels was largely shifted toward more negative membrane potentials upon application of increasing concentrations of RTG. The EC50 value was determined to be 4.1 µM with a Hill coefficient of 0.88, suggesting that one RTG molecule is sufficient to exert this activating effect on a single Kv7.2 channel (Fig. 2D). RTG in a concentration of 100 µM reduced the maximal Kv7.2 current amplitude, similar to that for Kv7.1 (Figs. 2B and 5A), which was in line with previous observations suggesting that an increase of the current amplitude for Kv7.2 by RTG was limited at strongly positive potentials (Tatulian et al., 2001). Kinetics of deactivation of Kv7.2 were significantly slowed by RTG, as was described by other groups previously for Kv7.2/3 coexpression (Main et al., 2000; Wickenden et al., 2000). A first-order exponential was fit to the deactivation time course at potentials between -80 and -120 mV. The time constants at -110 mV were 67 ± 5 ms before and 219 ± 31 ms after application of 100 µM RTG (p < 0.01, n = 4).
|
|
|
|
Effects of Point Mutations in Kv7.2 on RTG Sensitivity. Within the largely conserved pore region, there are only few residues that are different in Kv7.1 compared with Kv7.2 to -5 (Fig. 1). At these sites, we introduced point mutations in Kv7.2, substituting the respective amino acids from Kv7.1. In the S6 segment, the most intriguing alteration of the Kv7.1 sequence is a change of the highly conserved glycine 301, which is supposed to function as the gating hinge in a large spectrum of potassium channels, including the Shaker channel; the bacterial channels KcsA, MthK, and KvAP (Jiang et al., 2002); and even a bacterial sodium channel (Zhao et al., 2004). Mutation of Gly301 in Kv7.2 to an alanine, the corresponding amino acid in Kv7.1 (Q2[G301A]Q1), resulted in a nonfunctional channel, confirming the importance of this residue for channel gating in Kv7.2 channels. Some other S6 mutations showed little but significant alterations of the modification by RTG (e.g., a reduction of the negative shift by Q2[RLL291-3KTI]Q1) (see summary in Fig. 3).
In S5, the double mutation Q2[AW235-6TL]Q1 as well as the single mutation Q2[W236L]Q1 completely knocked out the RTG effect, whereas all other mutations did not change the reaction to RTG. Because Trp236 is located at the cytoplasmic end of S5, this result, together with the knockout of the RTG effect by substitution of the S6 segment, strongly suggests a binding of RTG to the cytoplasmic parts of S5 and S6 segments involving the channel's activation gate, which is supposed to be formed by residues downstream of the putative gating hinge Gly301. To identify further residues in these two protein regions, we mutated a few amino acids around Trp236 in S5 and the hydrophobic phenylalanines 304/305 in S6 to alanines, because RTG is highly lipophilic and therefore is supposed to bind to lipophilic residues in KCNQ channels. Q2[F304A] and Q2[I238A] showed a significantly increased sensitivity to RTG, whereas Q2[F305A] and Q2[Y237A] did not lead to functional channels. Q2[T234A] did not change the RTG effect significantly (Fig. 3).
Introduction of the RTG Binding Site in Kv7.1 or Kv7.1/Kv7.2 Chimeras. To evaluate the importance of Trp236 and Gly301 for the RTG effect, we introduced these residues in Kv7.1 and tested their impact on RTG sensitivity. For Q1[TL245-6AW]Q2 and Q1[L246W]Q2, the maximum effect of RTG on the voltage dependence of steady-state activation was a -5 mV shift (Fig. 3), but there was no clear relationship to the RTG concentration, so these small alterations have to be interpreted with caution. However, for Q1[L246W]Q2, we observed a strong, concentration-dependent reduction in current amplitude by RTG that was not observed to this extent for Kv7.1 or Kv7.2 (Figs. 5A and 2A), indicating that introduction of the tryptophan in this position increased this drug effect.
Introduction of a glycine at the corresponding hinge position in Kv7.1 (Q1[A336G]Q2) resulted in larger currents than observed for Kv7.1 WT channels, but we did not observe a significant effect of RTG. We did not observe stronger effects of RTG when both of these changes in S5 and S6 were simultaneously introduced into Kv7.1 (Fig. 3). Because the overall pore structures of Kv7.1 and Kv7.2 channels might be quite different, introduction of single amino acids may not be sufficient to induce a large RTG effect in Kv7.1. We therefore exchanged the whole S6 segment (Q1[S6]Q2). It is interesting to note that this chimera showed a clear RTG sensitivity; however, it revealed a different effect on channel gating than was observed for Kv7.2. Although the shift of the voltage dependence of activation was relatively small (-7.4-mV shift), a concentration-dependent, almost 3-fold increase in current amplitude was observed upon application of RTG (Fig. 5B). We next tried to combine Q1[S6]Q2 with Q1[L246W]Q2 and Q1[TL245-6AW]Q2, but these chimeras were nonfunctional, further suggesting considerable differences of the pore structures and gating mechanisms of Kv7.1 and Kv7.2. To further investigate the importance of the gating hinge for the RTG sensitivity, we constructed a chimera of Kv7.2 having an S6 segment of Kv7.1 with a glycine in position 336 (Kv7.1 numbering): Q2[S6]Q1[A336G]. For this mutation, the RTG-induced shift in voltage dependence—which was completely abolished in Q2[S6]Q1 (Fig. 4)—was largely restored (-13.6 mV shift), and current amplitudes were also significantly increased (Figs. 3 and 5C). These alterations strongly suggest a crucial role of the predicted flexibility of the S6 segment at the glycine hinge for RTG binding in Kv7.2 channels.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
) and the MthK (open conformation, Jiang et al., 2002) channels (for details, see Materials and Methods). As shown in Fig. 6, comparison of both channel conformations suggested the formation of a hydrophobic pocket between the cytoplasmic parts of S5 and S6 upon opening of the channel in which the energy-optimized RTG molecule could be docked manually. The pocket was induced by a kinking of the S6 helix at the gating hinge and a simultaneous conformational change of S5 (Fig. 6, B and C). In contrast, the parallel orientation of the S5 and S6 helices of the closed channel would not allow RTG binding (Fig. 6A). This model predicts a specific lipophilic interaction between the fluorophenyl ring of RTG and the aromatic Trp236 (Fig. 6B), which perfectly matches our electrophysiological experiments knocking out the RTG effect in Kv7.2 by the point mutation Q2[W236L]Q1. Furthermore, the model illustrates the importance of the flexibility of the S6 helix at the gating hinge (Gly301) to form the binding pocket, as was functionally suggested 1) by the knock-in of an RTG effect by introducing the complete S6 segment of Kv7.2 into Kv7.1 and particularly 2) by introducing a glycine at the gating hinge into the chimera Q2[S6]Q1. Furthermore, the relative increase of RTG sensitivity of the mutant Q2[F304A] underlines the importance of the helix distal to Gly301. Nevertheless, this computed model has to be interpreted with caution, because the RTG molecule is rather flexible and because the modeling revealed a considerable variability, particularly in the more cytoplasmic regions, when we tried to adapt the putative structure of Kv7.2 to the ones of KscA or MthK.
|
A second supporting evidence for an RTG binding site between the cytoplasmic parts of S5 and S6 segments derives from the biophysical mechanism of Kv7.2 activation. The large hyperpolarizing shift of the voltage dependence of steady-state activation can be well explained by a stabilization of the open-gate conformation induced by RTG binding in this channel region. In general, such a shift in voltage dependence is likely to result either from a direct effect on the voltage sensor or alternatively from affecting its coupling to the opening of the pore (i.e., the activation gate). A nice example for the latter possibility was given in a recent study by Zhao et al. (2004). When the glycine, considered to be the gating hinge in the S6 segment of a bacterial sodium channel, was replaced by a proline, which disrupts the 
-helical structure and reduces its flexibility, voltage-dependent activation of the channel was shifted by -51 mV. In Shaker potassium channels, large parallel shifts in the voltage dependence of channel activation by mutations at the gate have been observed (Hackos et al., 2002). Thus, the hyperpolarizing shift induced by RTG would be very well compatible with the hypothesis that RTG binds in between the S5 and S6 segments, involving the gate itself, thereby stabilizing the open channel conformation. In addition, the slowing of the deactivation time course by RTG could be well explained if RTG binds to the activation gate. The alterations in current amplitudes as observed for some of the mutants could be caused by decreases or increases in single-channel conductance, which would also fit well with the hypothesis of RTG binding in the pore region. For a discussion of the inactivation occurring in Q1[S6]Q2 see Seebohm et al. (2001).
Activation of a potassium channel at the resting membrane potential, as has been demonstrated for RTG (Main et al., 2000; Rundfeldt and Netzer, 2000; Wickenden et al., 2000; and this study), is a very potent anticonvulsant mechanism, because the resting potential is stabilized toward the potassium equilibrium potential (EK). None of the anticonvulsants that are in clinical use today exhibits such a mechanism of action. The efficacy of RTG has been shown in a large variety of seizure models (Rostock et al., 1996; Tober et al., 1996; Armand et al., 1999, 2000; Dost and Rundfeldt, 2000). Therefore, RTG, its derivatives, or other compounds with similar effects on neuronal potassium channels of the KCNQ family could be used as powerful drugs in the future treatment of epilepsy or other disorders going along with a membrane depolarization and hyperexcitability of the nervous system such as migraine, neuropathic pain, and stroke. Elucidation of the molecular mechanism of action of such compounds, as shown here for RTG, will contribute to a better understanding of drug-receptor interactions and should help to develop more specific and more effective drugs with fewer side effects.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: RTG, retigabine; WT, wild type;
Address correspondence to: Dr. Holger Lerche, Neurologische Klinik/Abteilung Angewandte Physiologie, Universität Ulm, Zentrum Klinische Forschung, Helmholtzstr. 8/1, 89081 Ulm, Germany. E-mail: holger.lerche{at}medizin.uni-ulm.de
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Armand V, Rundfeldt C, and Heinemann U (2000) Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 41: 28-33.
Brown DA and Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature (Lond) 283: 673-676.[CrossRef][Medline]
Dost R and Rundfeldt C (2000) The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation. Epilepsy Res 38: 53-66.[CrossRef][Medline]
Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, and MacKinnon R (1998) The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science (Wash DC) 280: 69-77.
Dupuis DS, Schroder RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, and Olesen SP (2002) Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS 204352. Eur J Pharmacol 437: 129-137.[CrossRef][Medline]
Guex N and Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714-2723.[CrossRef][Medline]
Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, et al. (2003) International Union of Pharmacology. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 55: 583-586.
Hackos DH, Chang TH, and Swartz KJ (2002) Scanning the intracellular S6 activation gate in the shaker K+ channel. J Gen Physiol 119: 521-532.
Hauser WA, Annegers JF, and Rocca WA (1996) Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71: 576-586.[Abstract]
Jentsch TJ (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30.[CrossRef][Medline]
Jiang Y, Lee A, Chen J, Cadene M, Chait BT, and MacKinnon R (2002) The open pore conformation of potassium channels. Nature (Lond) 417: 523-526.[CrossRef][Medline]
Lerche H, Biervert C, Alekov AK, Schleithoff L, Lindner M, Klinger W, Bretschneider F, Mitrovic N, Jurkat-Rott K, Bode H, et al. (1999) A reduced K+ current due to a novel mutation in KCNQ2 causes neonatal convulsions. Ann Neurol 46: 305-312.[CrossRef][Medline]
Lerche H, Weber YG, Jurkat-Rott K, and Lehmann-Horn F (2005) Ion channel defects in idiopathic epilepsies. Curr Pharm Des, in press.
Löscher W (1998) New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 342: 1-13.[CrossRef][Medline]
Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, and Burbidge SA (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262.
Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, et al. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223.[CrossRef][Medline]
Rundfeldt C and Netzer R (2000) The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 282: 73-76.[CrossRef][Medline]
Seebohm G, Scherer CR, Busch AE, and Lerche C (2001) Identification of specific pore residues mediating KCNQ1 inactivation. A novel mechanism for long QT syndrome. J Biol Chem 276: 13600-13605.
Straub H, Kohling R, Hohling J, Rundfeldt C, Tuxhorn I, Ebner A, Wolf P, Pannek H, and Speckmann E (2001) Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 44: 155-165.[CrossRef][Medline]
Tatulian L, Delmas P, Abogadie FC, and Brown DA (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J Neurosci 21: 5535-5545.
Tober C, Rostock A, Rundfeldt C, and Bartsch R (1996) D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303: 163-169.[CrossRef][Medline]
Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, and McKinnon D (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (Wash DC) 282: 1890-1893.
Wickenden AD, Yu W, Zou A, Jegla T, and Wagoner PK (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58: 591-600.
Zhao Y, Yarov-Yarovoy V, Scheuer T, and Catterall WA (2004) A gating hinge in Na+ channels: a molecular switch for electrical signaling. Neuron 41: 859-865.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  T. A. Jepps, I. A. Greenwood, J. D. Moffatt, K. M. Sanders, and S. Ohya Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles Am J Physiol Gastrointest Liver Physiol, July 1, 2009; 297(1): G107 - G115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Lange, J. Geissendorfer, A. Schenzer, J. Grotzinger, G. Seebohm, T. Friedrich, and M. Schwake Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels Mol. Pharmacol., February 1, 2009; 75(2): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Mackie and K. L. Byron Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention Mol. Pharmacol., November 1, 2008; 74(5): 1171 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gao, Q. Xiong, H. Sun, and M. Li Desensitization of Chemical Activation by Auxiliary Subunits: CONVERGENCE OF MOLECULAR DETERMINANTS CRITICAL FOR AUGMENTING KCNQ1 POTASSIUM CHANNELS J. Biol. Chem., August 15, 2008; 283(33): 22649 - 22658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Surges, K. E. Volynski, and M. C. Walker Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 13 - 24. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Maljevic, T. V. Wuttke, and H. Lerche Nervous system KV7 disorders: breakdown of a subthreshold brake J. Physiol., April 1, 2008; 586(7): 1791 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Wickenden, J. L. Krajewski, B. London, P. K. Wagoner, W. A. Wilson, S. Clark, R. Roeloffs, G. McNaughton-Smith, and G. C. Rigdon N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator Mol. Pharmacol., March 1, 2008; 73(3): 977 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xiong, H. Sun, Y. Zhang, F. Nan, and M. Li Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers PNAS, February 26, 2008; 105(8): 3128 - 3133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Ruff Upsetting the balance among membrane channels can produce hyperexcitability or inexcitability Neurology, November 27, 2007; 69(22): 2036 - 2037. [Full Text] [PDF]
|
|
|
|
|
|
T. V. Wuttke, K. Jurkat-Rott, W. Paulus, M. Garncarek, F. Lehmann-Horn, and H. Lerche Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations Neurology, November 27, 2007; 69(22): 2045 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perry, F. B. Sachse, and M. C. Sanguinetti Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator PNAS, August 21, 2007; 104(34): 13827 - 13832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Soldovieri, M. R. Cilio, F. Miceli, G. Bellini, E. Miraglia del Giudice, P. Castaldo, C. C. Hernandez, M. S. Shapiro, A. Pascotto, L. Annunziato, et al. Atypical Gating Of M-Type Potassium Channels Conferred by Mutations in Uncharged Residues in the S4 Region of KCNQ2 Causing Benign Familial Neonatal Convulsions J. Neurosci., May 2, 2007; 27(18): 4919 - 4928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Peretz, A. Sheinin, C. Yue, N. Degani-Katzav, G. Gibor, R. Nachman, A. Gopin, E. Tam, D. Shabat, Y. Yaari, et al. Pre- and Postsynaptic Activation of M-Channels By a Novel Opener Dampens Neuronal Firing and Transmitter Release J Neurophysiol, January 1, 2007; 97(1): 283 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schenzer, T. Friedrich, M. Pusch, P. Saftig, T. J. Jentsch, J. Grotzinger, and M. Schwake Molecular Determinants of KCNQ (Kv7) K+ Channel Sensitivity to the Anticonvulsant Retigabine J. Neurosci., May 18, 2005; 25(20): 5051 - 5060. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
, p < 0.05; 